Processa Pharmaceuticals (PCSA) Q2 2024 Earnings Report

330 Followers

PCSA Q2 2024 EPS Results

Actual EPS-$25.25

Consensus EPS-$25.25

Beat/MissMet expectations

One Year Ago EPS-$50.00

Actual Revenue$0.00

Expected Revenue―

Beat/Miss―

YoY Revenue Growth―

QuarterQ2 2024

Date08/28/2024

TimeBefore Open

Conference CallWednesday, August 28, 2024

No earnings call audio is available for this earnings event.

No slide deck is available for this earnings event.

No earnings call summary is available for this earnings event.

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change
Aug 06, 2026	2026 (Q2)	- / -1.19	-6.25	81.01% (+5.06)
Nov 05, 2025	2025 (Q3)	-2.00 / -1.81	-25.75	92.98% (+23.94)
Aug 07, 2025	2025 (Q2)	-0.22 / -0.25	-1.01	75.25% (+0.76)
Mar 27, 2025	2024 (Q4)	-0.84 / -0.77	-1.7	54.71% (+0.93)
Oct 30, 2024	2024 (Q3)	-25.00 / -25.75	-40	35.63% (+14.25)
Aug 28, 2024	2024 (Q2)	-25.25 / -25.25	-50	49.50% (+24.75)
Mar 28, 2024	2023 (Q4)	-1.60 / -1.65	-16.2	89.81% (+14.55)
Nov 08, 2023	2023 (Q3)	-0.10 / -0.08	-0.37	78.38% (+0.29)
Aug 10, 2023	2023 (Q2)	-0.15 / -0.10	-0.32	68.75% (+0.22)
May 11, 2023	2023 (Q1)	-0.28 / -0.18	-0.2	10.00% (+0.02)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed